Migea (Tolfenamic Acid)

Tolfenamic acid, the active ingredient in Migea, is a fenamate presented as an oral tablet for oral use. It is employed to relieve pain, reduce inflammation, and lower fever in adult patients with musculoskeletal and rheumatic conditions.

GNH USA supplies Migea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migea, a fenamate NSAID, acts on inflammatory pathways to manage several painful and inflammatory disorders. - Rheumatoid arthritis: reduction of joint pain, swelling and stiffness. - Osteoarthritis: alleviation of chronic joint discomfort and improved mobility. - Acute pain: rapid relief of moderate to severe pain episodes. - Inflammatory conditions: suppression of inflammation in soft tissues. - Fever: lowering of elevated body temperature associated with infection or inflammation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Renal impairment: reduced kidney function or acute renal failure. - Hematologic disorders: blood dyscrasias such as agranulocytosis. - Gastrointestinal ulceration or bleeding: potentially life‑threatening.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with impaired kidney function. - Monitor hepatic enzymes: watch for signs of liver injury during treatment. - Avoid in known hypersensitivity: discontinue immediately if allergic reactions occur. - Use with caution in the elderly: increased risk of gastrointestinal complications. - Store at ambient temperature: keep in the original pack, protect from moisture.

Tolfenamic acid may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs: additive gastrointestinal toxicity. - Corticosteroids: increased ulceration potential.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible decline in renal function. - Diuretics: may reduce efficacy and alter electrolyte balance. - Lithium: risk of elevated serum lithium levels.